Table 1 Overview of selected clinical trials of combined pharmacotherapy between mIDH1/2 inhibitors and other molecules
Drug combination | Phase | Number Enrolled | Inclusion criteria | Trail registration | Status | |
|---|---|---|---|---|---|---|
Ivosidenib | AZA | Ib/II | 131 | Newly diagnosed AML | NCT02677922 | Active, not recruiting |
venetoclax | II | 48 | AML | NCT03471260 | Recruiting | |
FLAG Chemotherapy | I | 25 | R/R AML | NCT04250051 | Not yet recruiting | |
CPX-351 | II | 30 | AML/MDS | NCT04493164 | Recruiting | |
gemcitabine + cisplatin | I | 40 | Cholangiocarcinoma | NCT04088188 | Recruiting | |
Decitabine/ ASTX727 + venetoclax | Ib/II | 84 | R/R AML | NCT04774393 | Not yet recruiting | |
Enasidenib | AZA | II | 50 | R/R AML | NCT03683433 | Recruiting |
AZA | II | 105 | MDS | NCT03383575 | Recruiting | |
Ruxolitinib | II | 32 | Myeloproliferative neoplasm | NCT04281498 | Not yet recruiting | |
CPX-351 | II | 18 | Relapsed AML | NCT03825796 | Recruiting | |
venetoclax | Ib/II | 48 | AML | NCT04092179 | Recruiting | |
Decitabine/ ASTX727 + venetoclax | Ib/II | 84 | R/R AML | NCT04774393 | Not yet recruiting | |